{"filing":{"accession_number":"0001193125-26-297211","cik":"0001831828","ticker":"VERA","company_name":"Vera Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-07","report_date":null,"primary_document":"vera-20260707.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1831828/000119312526297211/vera-20260707.htm"},"events":[{"id":16383,"run_id":14635,"accession_number":"0001193125-26-297211","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The disclosure announces FDA accelerated approval of TRUTAKNA (atacicept-vymj) for a specific indication in primary immunoglobulin A nephropathy. This is a material regulatory milestone and product approval event that would significantly affect investor assessment of the company's pipeline and commercial prospects, but does not fit the specific categories of earnings release, M\u0026A, impairment, or other named event types. It is clearly operational/strategic in nature.","company_name":"Vera Therapeutics, Inc.","ticker":"VERA","filing_date":"2026-07-07","form":"8-K","submitted_at":null,"items":[{"id":14469,"accession_number":"0001193125-26-297211","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces FDA accelerated approval of TRUTAKNA (atacicept-vymj) for a specific indication in primary immunoglobulin A nephropathy. This is a material regulatory milestone and product approval event that would significantly affect investor assessment of the company's pipeline and commercial prospects, but does not fit the specific categories of earnings release, M\u0026A, impairment, or other named event types. It is clearly operational/strategic in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:25:55.012099+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14469,"accession_number":"0001193125-26-297211","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces FDA accelerated approval of TRUTAKNA (atacicept-vymj) for a specific indication in primary immunoglobulin A nephropathy. This is a material regulatory milestone and product approval event that would significantly affect investor assessment of the company's pipeline and commercial prospects, but does not fit the specific categories of earnings release, M\u0026A, impairment, or other named event types. It is clearly operational/strategic in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:25:55.012099+00:00","company_name":"Vera Therapeutics, Inc.","ticker":"VERA","filing_date":"2026-07-07"}]}